Gary Phillips

Gary M.
Phillips is currently Chairman-Supervisory Board at Nanobiotix SA since 2021, Chairman at BioConnection BV, Independent Director at Aldeyra Therapeutics, Inc. since 2009, Director at Rheon Medical SA, Director at Helio Vision, Inc., Non-Executive Director at Oryn Therapeutics LLC, and Chief Business Officer at Anaveon AG since 2022.
Former roles include President & Chief Executive Officer at OrphoMed, Inc. from 2018 to 2022, Executive Chairman at Envisia Therapeutics, Inc., Director at Inotek Pharmaceuticals Corp., Independent Director at Zyla Life Sciences LLC from 2019 to 2020, Executive Director-Strategic Planning at Novartis Pharmaceuticals Corp.
from 2000 to 2002, President-U.S.
Surgical & Pharmaceuticals at Bausch & Lomb, Inc. from 2002 to 2008, Chief Strategy Officer & Executive Vice President at Keenova Therapeutics Plc, Managing Consultant at Towers Perrin, Inc. from 1997 to 1999, Head-Global Health & Healthcare at Forum Mondial de L'Economie from 2012 to 2013, Chief Strategy Officer & Executive Vice President at Mallinckrodt Brand Pharmaceuticals LLC from 2013 to 2018, President-North America at Reckitt Benckiser Pharmaceuticals, Inc. from 2011 to 2012, and Managing Consultant at Towers Watson & Co. Education includes an MBA from The Wharton School of the University of Pennsylvania in 1991, a doctorate from Perelman School of Medicine in 1992, and an undergraduate degree from The College of Arts & Sciences in 1987.